SCHEMBL524638

SCHEMBL524638

C=CCOc1ccc(CC(N)C(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 1/20 0.59
ITGA2B P08514 1/20 0.59
SLC7A5 Q01650 3/20 0.54
PTPN1 P18031 3/20 0.54
PTGS1 P23219 3/20 0.53
ALPI P09923 1/20 0.53
PKM P14618 1/20 0.53
XIAP P98170 1/20 0.53
TPH1 P17752 2/20 0.47
GRB2 P62993 1/20 0.47
ALOX15 P16050 3/20 0.46
HIF1A Q16665 3/20 0.46
KDM4E B2RXH2 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
USP2 O75604 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL455152 1.00 ITGB3 (0.59) ITGB3ITGA2BSLC7A5PTPN1PTGS1
SCHEMBL9784912 1.00 ITGB3 (0.59) ITGB3ITGA2BSLC7A5PTPN1PTGS1
Hydrochloric Acid SCHEMBL6775024 0.98 ITGB3 (0.58) ITGB3ITGA2BSLC7A5PTPN1PTGS1
SCHEMBL8195266 0.88 CA12 (0.46) ITGB3ITGA2BPTPN1CA12CA1
SCHEMBL25937506 0.88 NPC1 (0.47) ITGB3ITGA2BPTPN1CA12CA1
SCHEMBL19512314 0.88 SLC1A1 (0.58) ITGB3ITGA2BSLC7A5PTPN1CA12
SCHEMBL19512315 0.88 SLC1A1 (0.58) ITGB3ITGA2BSLC7A5PTPN1CA12
SCHEMBL19512313 0.88 SLC1A1 (0.58) ITGB3ITGA2BSLC7A5PTPN1CA12
SCHEMBL16060571 0.86 ITGB3 (0.61) ITGB3ITGA2BSLC7A5PTPN1PTGS1
SCHEMBL1944103 0.86 LDHA (0.57) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325632-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES Synthorx, Inc. (US) 2025-10-23 US claimed
US-20250325633-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES Synthorx, Inc. (US) 2025-10-23 US claimed
US-12377131-B2 Cytokine conjugates for the treatment of autoimmune diseases Synthorx, Inc. (US) 2025-08-05 US claimed
US-12318431-B2 Cytokine conjugates for the treatment of proliferative and infectious diseases Synthorx, Inc. (US) 2025-06-03 US claimed
US-20240082359-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES Synthorx, Inc. (US) 2024-03-14 US claimed
US-11919934-B2 IL-15 conjugates and uses thereof Synthorx, Inc. (US) 2024-03-05 US claimed
US-20230302089-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES Synthorx, Inc. (US) 2023-09-28 US claimed
US-11701407-B2 Cytokine conjugates for the treatment of proliferative and infectious diseases Synthorx, Inc. (US) 2023-07-18 US claimed
US-11622993-B2 Cytokine conjugates for the treatment of autoimmune diseases Synthorx, Inc. (US) 2023-04-11 US claimed
EP-4041247-A1 EUKARYOTIC SEMI-SYNTHETIC ORGANISMS The Scripps Research Institute (US) 2022-08-17 EP claimed
CN-111194322-A Cytokine conjugates for the treatment of proliferative and infectious diseases 辛索克斯公司 2020-05-22 CN claimed
CN-111183149-A Cytokine conjugates for the treatment of autoimmune diseases 辛索克斯公司 2020-05-19 CN claimed
WO-2019165453-A1 IL-15 CONJUGATES AND USES THEREOF Synthorx, Inc. (US) 2019-08-29 WO claimed
WO-2019028425-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES Synthorx, Inc. (US) 2019-02-07 WO claimed
WO-2019028419-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES Synthorx, Inc. (US) 2019-02-07 WO claimed
EP-2665744-B1 MACROCYCLIC COMPOUNDS WITH A HYBRID PEPTIDIC/NON-PEPTIDIC BACKBONE AND METHODS FOR THEIR PREPARATION UNIV ROCHESTER (US) 2015-04-08 EP claimed
US-8986953-B2 Macrocyclic compounds with a hybrid peptidic/non-peptidic backbone and methods for their preparation UNIVERSITY OF ROCHESTER (US) 2015-03-24 US claimed
US-20130330773-A1 MACROCYCLIC COMPOUNDS WITH A HYBRID PEPTIDIC/NON-PEPTIDIC BACKBONE AND METHODS FOR THEIR PREPARATION NATIONAL SCIENCE FOUNDATION 2013-12-12 US claimed
EP-2665744-A2 MACROCYCLIC COMPOUNDS WITH A HYBRID PEPTIDIC/NON-PEPTIDIC BACKBONE AND METHODS FOR THEIR PREPARATION UNIVERSITY OF ROCHESTER (US) 2013-11-27 EP claimed
WO-2012100176-A2 MACROCYCLIC COMPOUNDS WITH A HYBRID PEPTIDIC/NON-PEPTIDIC BACKBONE AND METHODS FOR THEIR PREPARATION UNIVERSITY OF ROCHESTER (US) 2012-07-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325633-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES IL2, IL2RA, IL15 ITGB3 1343/4885ITGA2B 284/4885SLC7A5 2484/4885
US-20230302089-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES IL2, IL2RA, IL15 ITGB3 1343/4885ITGA2B 284/4885SLC7A5 2484/4885
US-11701407-B2 Cytokine conjugates for the treatment of proliferative and infectious diseases IL2, IL2RA, IL36G ITGB3 959/4885ITGA2B 286/4885SLC7A5 1836/4885
US-12318431-B2 Cytokine conjugates for the treatment of proliferative and infectious diseases IL2, IL2RA, IL36G ITGB3 959/4885ITGA2B 286/4885SLC7A5 1836/4885
US-20240082359-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES IL2, IL2RA, IL36G ITGB3 959/4885ITGA2B 286/4885SLC7A5 1836/4885
US-20130330773-A1 MACROCYCLIC COMPOUNDS WITH A HYBRID PEPTIDIC/NON-PEPTIDIC BACKBONE AND METHODS FOR THEIR PREPARATION MICA, VIP, NPEPPS ITGB3 4870/4885ITGA2B 4855/4885SLC7A5 964/4885
US-20250325632-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES IL2, IL2RA, IL36G ITGB3 959/4885ITGA2B 286/4885SLC7A5 1836/4885
US-12377131-B2 Cytokine conjugates for the treatment of autoimmune diseases IL2, IL2RA, IL15 ITGB3 1343/4885ITGA2B 284/4885SLC7A5 2484/4885
US-11622993-B2 Cytokine conjugates for the treatment of autoimmune diseases IL2, IL2RA, IL15 ITGB3 1343/4885ITGA2B 284/4885SLC7A5 2484/4885
US-11919934-B2 IL-15 conjugates and uses thereof IL15, IL15RA, IL2 ITGB3 225/4885ITGA2B 250/4885SLC7A5 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.